biopharma-reporter2h
Setback for Inhibikase Parkinson’s therapy
Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.
biopharma-reporter8h
Atalanta Therapeutics raises $97 million to advance RNAi therapies for CNS disorders
The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...
biopharma-reporter2d
Akero Therapeutics succeeds with MASH liver treatment at phase 2
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
biopharma-reporter2d
Roche’s Elevidys demonstrates significant benefits for DMD patients in Phase 3
The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...
biopharma-reporter7d
Viralgen and Axovia collaborate to manufacture gene therapy for rare disease vision loss
The Spanish contract development and manufacturing organization (CDMO) Viralgen and UK gene therapy developer Axovia Therapeutics announced yesterday that they have joined forces to boost the ...
biopharma-reporter7d
Amylyx Pharmaceuticals gets FDA go ahead for phase 1 ALS trial
The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, designed to treat amyotrophic lateral sclerosis (ALS), after the FDA lifted its ...